Objective-To reconstitute a dysfunctional form of complement factor C3 in a patient with a systemic lupus erythematosus (SLE) 
A minute inflammatory reaction was observed after the second, third and fourth treatment period in that the fingers were more swollen and the arthralgia was worse.
The treatment during the eight month period resulted in no obvious clinical improvement of the propositus clinical condition except that the patient's Raynaud's phenomena seemed to disappear. The disease activity assessed by the SLE Disease Activity Index (SLEDAI)6 remained at the same level before and after the treatment period (score 6). However, the patient has subjectively improved and the fatigue has vanished. Before the treatment the propositus was unable to work for five years but she has now returned to her previous occupation as a physiotherapist. Reconstitution of the alternative pathway of complement by plasma infusions given to a patient with an SLE-like syndrome Figure 2 Tissue deposition ofC3fragments during the second session ofplasma infusions. No significant deposits ofC3 was found before the session was started (fig 2A) . Two days after the second plasma treatment when 4 x 500 ml ofplasma were infused, biopsies taken close to the previous biopsies, showed significant granular deposits of C3fragments at the same location as previously found IgG and IgM deposits ( fig 2B) . levels. The C3d generation was only detected after the final four sessions.
DEPOSITION OF c3 FRAGMENTS IN THE SKIN AFT1ER PLASMA INFUSIONS
Before the second session of plasma infusions, skin biopsies showed deposition of IgG and IgM at the dermis-epidermis junction. No significant deposits of C3 was found (fig 2A) . After the second plasma treatment, biopsies taken close to the previous biopsies, showed significant granular deposits of C3 fragments at the same location as the immunoglobulins (fig 2B) . (fig 1B) . The patients IL-6 levels were consistently increased already before plasma infusions (56-113 ng/ml). The concentrations increased after session II-IV with peak levels ranging from 93 to 234 ng/ml (not shown).
SERUM IC-C3 AND IC-IGG LEVELS
Initially, the serum levels of IgG-and C3-containing ICs were exceedingly high with peak levels reaching 9 0 ,ug/ml and 0 7 ,ug/ml, respectively (normal values < 1 2 ,ug/ml [IgG]; < 94 ng/ml [C3]). During the plasma treatment the levels gradually decreased and were half the original levels after the last plasma infusion (fig 1 C) . During the year preceding the plasma treatment the IC levels were assessed four times ranging between 8-9-9-5 pLg/ml and 06-0-8 ,ug/ml, respectively.
HAEMATOLOGICAL AND INFLAMMATORY PARAMETERS
No consistent changes in the counts of mononuclear or polynuclear leucocytes, eosinophilic granulocytes or platelets were observed. The haemoglobin concentration did not change (1 and 5) or decreased, due to dilution, to a nadir of 88% of the original level (2-4). The sedimentation rate was not increased and C reactive protein was marginally elevated during the five sessions.
Discussion
Reconstitution with complement components of patients with hereditary complement deficiencies combined with SLE-like syndromes may prove therapeutically beneficial, since complement is crucial for the handling and elimination of IC." A precedent to plasma treatment was observed in a case of therapyresistant SLE with a homozygous C2 deficiency. Full clinical remission was seen over a period of 45 months involving repeated cycles of fresh plasma therapy. 12 The purpose of the present study was The clinical efficacy of the treatment when formally assessed was not obvious.6 However, the fatigue which was the most disabling symptom, gradually disappeared and after plasma therapy our patient has experienced improved well being and function, including working capacity and the ability to carry out activities of daily living. These therapeutic effects might be the result of a decreased immune complex load.
However, the possibility exists that plasma infusions could actually worsen tissue damage. Our patient responded with fever, nausea, vomiting, diarroea and a transient haematuria and proteinuria after the first plasma infusion session during which the patient received only 500 ml of plasma. These findings indicate that plasma treatment might be potentially hazardous and suggest that such treatment in patients with complement deficiencies should be carried out with initially very low doses followed by gradually increased amounts.
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